Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

The current epidemic of non-alcoholic fatty liver disease (NAFLD) is reshaping the field of
hepatology all around the world. The widespread diffusion of metabolic risk factors such as …

Hypertension is common among patients with diabetes, with the prevalence depending on
type and duration of diabetes, age, sex, race/ethnicity, BMI, history of glycemic control, and …

The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to have
reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect …

Obesity is a chronic metabolic disease characterised by an increase of body fat stores. It is a
gateway to ill health, and it has become one of the leading causes of disability and death …

Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor
agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight …

The Clinical Practice Guidelines (CPG) propose recommendations for the diagnosis,
treatment and follow-up of non-alcoholic fatty liver disease (NAFLD) patients and are the …

Obesity has tripled over the past 40 years to become a major public health issue, as it is
linked with increased mortality and elevated risk for various physical and neuropsychiatric …

Клинические рекомендации уже давно вошли в число рабочих инструментов
современного врача, помогая ему быстро ориентироваться в наиболее эффективных …

Introduction Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss
can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in …